Sjögren’s syndrome (SS) is an important but poorly recognized cause of peripheral neuropathy. Several forms of peripheral nerve dysfunction occur, including trigeminal sensory neuropathy, mononeuropathy multiplex, distal sensorimotor polyneuropathy and pure sensory neuronopathy. The pathological findings vary and the definite treatment is not known. Here we present 4 cases of acute ataxic sensory polyneuropathy with SS, and the experience of treatment with plasmapheresis (PP). The 4 patients were all females; ages ranged from 30 to 58 years. All had prominent loss of kinesthetic and proprioceptive sensation. The course ranged from acute to subacute onset. Patients were treated with 5–9 sessions of PP. Two patients with initiation of treatment within 2 weeks of onset showed dramatic and sustained responses after PP, while the other 2 had no detectable effects. Our experience showed that PP should be considered in patients who present with sensory neuropathy associated with SS, and the treatment should be given as early as possible.

Keywords:
Ataxic sensory neuropathy, Sjögren’s syndrome, Plasmapheresis
1.
Fox RI: Clinical features, pathogenesis, and treatment of Sjögren’s syndrome. Curr Opin Rheumatol 1996;8:438–445.
2.
Andonopoulos AP, Lagos G, Drosos AA, Moutsopoulos HM: The spectrum of neurological involvement in Sjögren’s syndrome. Br J Rheumatol 1990;29:21–23.
3.
Hull RG, Morgan SH, Harding AE, Hughes GR: Sjögren’s syndrome presenting as a severe sensory neuropathy including involvement of the trigeminal nerve. Br J Rheumatol 1984;23:301–303.
4.
Malinow K, Yannakakis GD, Glusman SM, Edlow DW, Griffin J, Pestronk A, Powell DL, Ramsey-Goldman R, Eidelman BH, Medsger TAJ: Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren’s syndrome. Ann Neurol 1986;20:535–537.
5.
Mellgren SI, Conn DL, Stevens JC, Dyck PJ: Peripheral neuropathy in primary Sjögren’s syndrome. Neurology 1989;39:390–394.
6.
Kaplan JG, Rosenberg R, Reinitz E, Buchbinder S, Schaumburg HH: Invited review: Peripheral neuropathy in Sjögren’s syndrome. Muscle Nerve 1990;13:570–579.
7.
Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, Mancia D: Peripheral neuropathy associated with primary Sjögren’s syndrome. J Neurol Neurosurg Psychiatry 1994;57:983–986.
8.
Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S: Preliminary criteria for the classification of Sjögren’s syndrome: Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340–347.
9.
Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O’Brien PC, Grina LA, Palumbo PJ, Swanson CJ: Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590–596.
10.
Guillain-Barré Syndrome Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096–1104.
11.
O’Leary CP, Willison HJ: Autoimmune ataxic neuropathies (sensory ganglionopathies). Curr Opin Neurol 1997;10:366–370.
12.
Griffin JW, Cornblath DR, Alexander E, Campbell J, Low PA, Bird S, Feldman EL: Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren’s syndrome. Ann Neurol 1990;27:304–315.
13.
Gabriel D, Gregson N, Hughs R: Sensory neuropathy and anti-Hu antibodies in a patient with seminoma. Eur J Neurol 1996;3:471–474.
14.
Molina JA, Benito-Leon J, Bermejo F, Jimenez-Jimenez FJ, Olivan J: Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry 1996;60:699.
15.
Pascual J, Cid C, Berciano J: High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjögren’s syndrome. Neurology 1998;51:650–651.
16.
Farrell DA, Medsger TAJ: Trigeminal neuropathy in progressive systemic sclerosis. Am J Med 1982;73:57–62.
17.
Fox RI: Sjögren’s syndrome. Curr Opin Rheumatol 1995;7:409–416.
18.
Ramos-Remus C, Suarez-Almazor M, Russell AS: Low tear production in patients with diabetes mellitus is not due to Sjögren’s syndrome. Clin Exp Rheumatol 1994;12:375–380.
19.
Bakchine S, Mas JL, Rottembourg R, Wechsler B, Le Charpentier Y, Derouesne C: Polyneuropathy disclosing primary Gougerot-Sjögren syndrome: Treatment by plasma exchange. Rev Neurol (Paris) 1987;143:839–840.
20.
Konttinen YT, Kinnunen E, von Bonsdorff M, Lillqvist P, Immonen I, Bergroth V, Segerberg-Konttinen M, Friman C: Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjögren’s syndrome. Arthritis Rheum 1987;30:339–344.
21.
Dyck PJ, Prineas J, Pollard J: Chronic inflammatory demyelinating polyradiculoneuropathy; in Dyck PJ, Thomas PK, Griffin J, Low PA, Poduslo JF (eds): Peripheral Neuropathy. Philadephia, Saunders, 1993, pp 1498–1517.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.